Ralf Lutterbuese

2.0k total citations
15 papers, 876 citations indexed

About

Ralf Lutterbuese is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Ralf Lutterbuese has authored 15 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Oncology and 6 papers in Immunology. Recurrent topics in Ralf Lutterbuese's work include Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (4 papers). Ralf Lutterbuese is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (4 papers). Ralf Lutterbuese collaborates with scholars based in Germany, United States and Switzerland. Ralf Lutterbuese's co-authors include Peter Kufer, Patrick A. Baeuerle, Bernd Schlereth, Tobias Raum, Roman Kischel, Klaus Brischwein, Grit Lorenczewski, Andreas Wolf, Doris Rau and Petra Kleindienst and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Ralf Lutterbuese

15 papers receiving 807 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ralf Lutterbuese Germany 10 615 523 393 283 76 15 876
Bernd Schlereth Germany 14 994 1.6× 832 1.6× 622 1.6× 432 1.5× 97 1.3× 23 1.4k
Andrew Scott United States 10 748 1.2× 176 0.3× 707 1.8× 339 1.2× 58 0.8× 19 1.1k
Casey W. Shuptrine United States 10 264 0.4× 179 0.3× 294 0.7× 225 0.8× 40 0.5× 13 588
Pamela A. Davol United States 13 282 0.5× 195 0.4× 196 0.5× 226 0.8× 44 0.6× 24 558
Sylvia Herter Switzerland 11 369 0.6× 345 0.7× 332 0.8× 236 0.8× 90 1.2× 35 765
Ekkehard Moessner Switzerland 10 264 0.4× 229 0.4× 248 0.6× 199 0.7× 32 0.4× 20 614
Quentin Lecocq Belgium 17 574 0.9× 523 1.0× 323 0.8× 281 1.0× 102 1.3× 23 918
Michela Silacci Switzerland 11 179 0.3× 379 0.7× 208 0.5× 358 1.3× 25 0.3× 13 702
Slava Stamova Germany 13 617 1.0× 177 0.3× 388 1.0× 163 0.6× 146 1.9× 22 752
Dirk Zboralski United States 13 503 0.8× 149 0.3× 218 0.6× 332 1.2× 75 1.0× 22 937

Countries citing papers authored by Ralf Lutterbuese

Since Specialization
Citations

This map shows the geographic impact of Ralf Lutterbuese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Lutterbuese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Lutterbuese more than expected).

Fields of papers citing papers by Ralf Lutterbuese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf Lutterbuese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Lutterbuese. The network helps show where Ralf Lutterbuese may publish in the future.

Co-authorship network of co-authors of Ralf Lutterbuese

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Lutterbuese. A scholar is included among the top collaborators of Ralf Lutterbuese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Lutterbuese. Ralf Lutterbuese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Sternjak, Alexander, Fei Lee, Joachim Wahl, et al.. (2017). Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin. Cancer Research. 77(13_Supplement). 3630–3630. 1 indexed citations
2.
Arvedson, Tara, Mercedesz Balázs, Kurt A. Black, et al.. (2017). Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing. Cancer Research. 77(13_Supplement). 55–55. 23 indexed citations
3.
Nolan-Stevaux, Olivier, Lily Liu, Suzanne Coberly, et al.. (2016). Abstract 585: Assessing ENPP3 as a renal cancer target for bispecific T-cell engager (BiTE) therapy. Cancer Research. 76(14_Supplement). 585–585. 1 indexed citations
4.
Friedrich, Matthias, Tobias Raum, Ralf Lutterbuese, et al.. (2012). Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens. Molecular Cancer Therapeutics. 11(12). 2664–2673. 109 indexed citations
5.
Lutterbuese, Ralf, Matthias G. Friedrich, Roman Kischel, et al.. (2011). Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer. Cancer Research. 71(8_Supplement). 4561–4561. 1 indexed citations
6.
Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2010). T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proceedings of the National Academy of Sciences. 107(28). 12605–12610. 123 indexed citations
7.
Amann, Maria, Grit Lorenczewski, Klaus Brischwein, et al.. (2009). Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release. Journal of Immunotherapy. 32(5). 452–464. 43 indexed citations
8.
Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2009). Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA. Journal of Immunotherapy. 32(4). 341–352. 64 indexed citations
9.
Brandl, Christian, Nadja Prang, Ralf Lutterbuese, et al.. (2008). Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leukemia Research. 33(3). 465–473. 58 indexed citations
10.
Amann, Maria, Klaus Brischwein, Petra Lutterbuese, et al.. (2008). Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Research. 68(1). 143–151. 68 indexed citations
11.
Lutterbuese, Ralf, et al.. (2008). Conversion of Cetuximab and Trastuzumab into T cell-engaging BiTE antibodies creates novel drug candidates with superior anti-tumor activity. 68. 2402–2402. 3 indexed citations
12.
Hammond, Scott A., Ralf Lutterbuese, Shannon Roff, et al.. (2007). Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. Cancer Research. 67(8). 3927–3935. 66 indexed citations
13.
Baeuerle, Patrick A., Maria Amann, Klaus Brischwein, et al.. (2007). Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3. Molecular Cancer Therapeutics. 6. 3 indexed citations
14.
Brischwein, Klaus, Bernd Schlereth, Andreas Wolf, et al.. (2005). MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecular Immunology. 43(8). 1129–1143. 212 indexed citations
15.
Schlereth, Bernd, Iduna Fichtner, Grit Lorenczewski, et al.. (2005). Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct. Cancer Research. 65(7). 2882–2889. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernd Schlereth Breakdown of academic impact, for papers by Andrew Scott Breakdown of academic impact, for papers by Casey W. Shuptrine Breakdown of academic impact, for papers by Pamela A. Davol Breakdown of academic impact, for papers by Sylvia Herter Breakdown of academic impact, for papers by Ekkehard Moessner Breakdown of academic impact, for papers by Quentin Lecocq Breakdown of academic impact, for papers by Michela Silacci Breakdown of academic impact, for papers by Slava Stamova Breakdown of academic impact, for papers by Dirk Zboralski
Rankless by CCL
2026